Market revenue in 2023 | USD 21.9 million |
Market revenue in 2030 | USD 51.7 million |
Growth rate | 13% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.07% in 2023. Horizon Databook has segmented the Denmark immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Denmark is a country with 5.5 million people. There are only about 20–25 clinical neurophysiologists and neurologists working in private surgery in Denmark, there are 20 neurology departments, 611 beds, and large outpatient clinics.
There are about 8,000 new cases of dementia among people aged 65 and above every year. This corresponds to about 22 new cases every day throughout the duration of the year. The number of dementia patients has increased over time as a result of rapidly aging population and rising life expectancy.
According to data from the Danish Health and Medicines Authority, there were around 31,850 cases of dementia reported among adults 65 and older in 2011 and approximately 37,600 cases in 2018. This growth is linked to geriatric population and rising life expectancy.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Denmark immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account